Solithera’s Prospects Look Grim Following Complete Response Letter

Even if Cempra has the funds to conduct another trial, there is no guarantee for approval; if approved, solithromycin’s labeling would likely limit use of the community-acquired pneumonia antibiotic.

The US FDA's complete response letter for Cempra Inc.'s community-acquired bacterial pneumonia (CABP) antibiotic Solithera (solithromycin) puts the company on a difficult and uncertain path forward.

The agency went against the recommendations of its advisory committee, apparently unwilling to wait until Phase IV to sort out...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip